BioLife Signs Distribution Agreement With StemCell

BioLife Solutions has entered into a non-exclusive distribution agreement with StemCell Technologies.

Mike Rice, chairman and CEO of BioLife, said: We’re very pleased to now have our products represented and distributed throughout the world by StemCell and their sub-distributor partners. Their MethoCult reagent systems have become worldwide standards and we look forward to their distribution network’s ability to help our HypoThermosol and CryoStor product platforms achieve the same level of product adoption.

Allen Eaves, founder and chairman of the StemCell Group, said: Our interest in BioLife Solutions has grown as we’ve seen their products adopted by numerous customers in our strategic markets. We also conducted several comparative cell preservation experiments with CryoStor against other freeze media and were very impressed by the performance of CryoStor in improving post-thaw cell viability and recovery.

We feel that the robust regulatory and quality footprint of serum-free and protein-free CryoStor and HypoThermosol will increasingly be valued by researchers and clinicians around the world.